Subscribe
Beltway Confidential

When we get a coronavirus vaccine, thank intellectual property rights

By
Published
Add Washington Examiner on Google
When we get a coronavirus vaccine, thank intellectual property rights

Good news in the fight against the novel coronavirus is finally starting to build.

Now in trials, AstraZeneca believes it will be able to seek regulatory approval for its vaccine by the end of the year. Also in trials, BioNTech believes the vaccine it is producing with Pfizer could be ready for administration by December. Johnson & Johnson has begun human trials of its vaccine and anticipates phase 3 trials by the end of September.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.

Tag:

Anthony Fauci COVID-19 Intellectual Property Pharmaceutical Industry Vaccines